The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence

Blog Article

Rheumatoid arthritis (RA) is an immune-mediated inflammatory (autoimmune) rheumatic disease of unknown etiology, which Circulation Hose is characterized by chronic erosive arthritis (synovitis) and systemic damage of internal organs and leads to early disability and shorter life expectancy in patients.Much attention is paid to studying the role of interleukin 6 (IL6) in the spectrum of proinflammatory cytokines involved in the pathogenesis of RA.The clinical introduction of anti-IL receptor monoclonal antibodies, such as tocilizumab and sarilumab, that inhibit the activity of this cytokine, is an important step in the improvement of RA treatment.

The review considers the data from the main randomized controlled trials of the efficacy and safety of sarilumab in RA and discusses the prospects for using the drug to Bras treat this disease.